Nexgel

Q2 FY2026 EarningsQ2 FY26 results missed consensus estimates significantly, with revenue of $3.69M falling -14.48% short of the $4.32M expected. The net loss of $2.87M was substantially wider than the anticipated $1.01M loss, driven by supply chain constraints in the newly formed BioNX Surgical division and one-time transaction costs. A current backlog of $795,000 and the strategic recall of SilverSeal inventory suggest near-term execution headwinds despite management's focus on higher-margin hospital channels.